ReviewBiomedicines2022
What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review (Part 6): Correlation of PD-L1 Expression with the Status of Mismatch Repair System,
Open access · goldAbstract readReview
In one paragraph
Review in Biomedicines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.7field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 27 citations in OpenAlex.
- PD-L1 Expression in Prostate Cancer: Anatomopathological Features, Methodological Pitfalls, and Therapeutic Potential.International journal of molecular sciences · 2026Review
- Identification of prognostic genes associated with mitochondria and macrophage polarization in prostate adenocarcinoma based on transcriptome and Mendelian randomization analysis.Discover oncology · 2025Article
- MXene-based electrochemical sensors for cancer biomarker detection: current trends, challenges, and future directions.Mikrochimica acta · 2025Review
- SPOP and MMR/MSI alterations in prostate cancer: relationship with PD-L1, TILs and AR expression.Pathologica · 2025Article
- Review
- Review
- The Evolving Molecular Landscape and Actionable Alterations in Urologic Cancers.Current oncology (Toronto, Ont.) · 2024Review
- Androgen Insensitivity Syndrome with Bilateral Gonadal Sertoli Cell Lesions, Sertoli-Leydig Cell Tumor, and Paratesticular Leiomyoma: A Case Report and First Systematic Literature Review.Journal of clinical medicine · 2024Article
- Mutual regulation of PD-L1 immunosuppression between tumor-associated macrophages and tumor cells: a critical role for exosomes.Cell communication and signaling : CCS · 2024Review
- DNA Damage Repair Pathways in Prostate Cancer: A Narrative Review of Molecular Mechanisms, Emerging Biomarkers and Therapeutic Targets in Precision Oncology.International journal of molecular sciences · 2023Review
- A Case of Prostatic Signet-Ring Cell-like Carcinoma with Pagetoid Spread and Intraductal Carcinoma and Long-Term Survival: PD-L1 and Mismatch Repair System Proteins (MMR) Immunohistochemical Evaluation with Systematic Literature Review.Journal of personalized medicine · 2023Review
- Immunotherapy in Prostate Cancer: State of Art and New Therapeutic Perspectives.Current oncology (Toronto, Ont.) · 2023Review
- Detection and Molecular Characterization of Circulating Tumour Cells: Challenges for the Clinical Setting.Cancers · 2023Review
- Immunotherapy for Prostate Cancer: A Current Systematic Review and Patient Centric Perspectives.Journal of clinical medicine · 2023Article
- SPOP regulates the expression profiles and alternative splicing events in human hepatocytes.Open life sciences · 2023Article
- Immunotherapy in Advanced Prostate Cancer-Light at the End of the Tunnel?International journal of molecular sciences · 2022Review
- Assessing the Mechanism of Action of "Fructus Ligustri Lucidi-Cuscutae Semen" in Prostate Cancer Treatment Using Network Pharmacology and Molecular Docking.Computational and mathematical methods in medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 10 institutions in 3 countries.
Andrea PalicelliPathology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy.ORCID 0000-0003-2299-5160
Stefania CrociClinical Immunology, Allergy and Advanced Biotechnologies Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy.ORCID 0000-0002-8622-0439
Alessandra BisagniPathology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy.
Eleonora ZanettiPathology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy.ORCID 0000-0002-3483-130X
Dario De BiaseDepartment of Pharmacy and Biotechnology (FABIT), University of Bologna, 40126 Bologna, Italy.ORCID 0000-0002-0609-8817
Beatrice MelliFertility Center, Department of Obstetrics and Gynecology, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy.ORCID 0000-0003-1366-2081
Francesca SanguedolcePathology Unit, Policlinico Riuniti, University of Foggia, 71122 Foggia, Italy.
Moira RagazziPathology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy.ORCID 0000-0002-8761-9265
Magda ZanelliPathology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy.ORCID 0000-0002-8733-9933
Alcides ChauxDepartment of Scientific Research, School of Postgraduate Studies, Norte University, Asuncion 1614, Paraguay.
Sofia Cañete-PortilloDepartment of Pathology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Maria Paola BonasoniPathology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy.
Stefano AscaniPathology Unit, Azienda Ospedaliera Santa Maria di Terni, University of Perugia, 05100 Terni, Italy.
Antonio De LeoMolecular Diagnostic Unit, Azienda USL Bologna, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, 40138 Bologna, Italy.ORCID 0000-0002-3761-5135
Guido GiordanoMedical Oncology Unit, Department of Medical and Surgical Sciences, University of Foggia, 71122 Foggia, Italy.
Matteo LandriscinaMedical Oncology Unit, Department of Medical and Surgical Sciences, University of Foggia, 71122 Foggia, Italy.ORCID 0000-0003-0591-9799
Giuseppe CarrieriDepartment of Urology and Renal Transplantation, University of Foggia, 71122 Foggia, Italy.
Luigi CormioDepartment of Urology and Renal Transplantation, University of Foggia, 71122 Foggia, Italy.
Jatin GandhiDepartment of Pathology and Laboratory Medicine, University of Washington, Seattle, WA 98195, USA.
Davide NicoliMolecular Biology Laboratory, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy.
Enrico FarnettiMolecular Biology Laboratory, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy.
Simonetta PianaPathology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy.ORCID 0000-0003-4875-6977
Alessandro TafuniPathology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy.ORCID 0000-0002-0183-757X
Martina BonaciniClinical Immunology, Allergy and Advanced Biotechnologies Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy.ORCID 0000-0002-6830-6781
Azienda Sanitaria Unità Locale di Reggio Emilia · ITUniversity of Foggia · ITAzienda USL di Bologna · ITUniversidad del Norte · PYUniversity of Alabama at Birmingham · USUniversity of Bologna · ITUniversity of Modena and Reggio Emilia · ITUniversity of Parma · ITUniversity of Perugia · ITUniversity of Washington · US
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pembrolizumab (anti-PD-1) is allowed in selected metastatic castration-resistant prostate cancer (PC) patients showing microsatellite instability/mismatch repair system deficiency (MSI-H/dMMR).
Indexed as
BRCAcancergenesimmunotherapymicrosatellite instabilitymismatch repairPD-L1prostatePTEN
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.